Details of the Drug

General Information of Drug (ID: DM2POTE)

Drug Name

Colchicine

Synonyms

Colchicin; Colchicina; Colchicinum; Colchineos; Colchisol; Colchysat; Colcin; Colcrys; Colsaloid; Colstat; Condylon; Goutnil; Kolkicin; LOC; Binds to tubulin; Colchicin [German]; Colchicina [Italian]; Colchicine [JAN]; Inhibits microtubular assembly; Spindle poison; C 9754; Colchicine (TN); Colchicine, Colchicum autumnale; MPC-004; N-Acetyl trimethylcolchicinic acid methylether; Colchicine (JP15/USP); Colchicine, (R)-Isomer; Benzo(a)heptalen-9(5H)-one; Colchicine, (+-)-Isomer; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-5,6,7,9-tetrahydrobenzo[a]heptalen-7-yl]acetamide; N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide; N-[(7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl]acetamide; N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[.alpha.]heptalen-7-yl)-acetamide; N-((7S)-5,6,7,9-tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo(a)heptalen-7-yl)-acetamide; (S)-N-(5,6,7,9-Tetrahydro-1,2,3,10-tetramethoxy-9-oxobenzo[a]heptalen-7-yl)acetamide; 7-alpha-H-Colchicine; 7.alpha.H-Colchicine; 7alphaH-Colchicine

Indication

Disease Entry	ICD 11	Status	REF
Acute gout flare	FA25.0	Approved	[1]
Acute gouty arthritis	FA25.0	Approved	[2]
Gout	FA25	Approved	[3]
Coronavirus Disease 2019 (COVID-19)	1D6Y	Phase 2	[4]
Familial Mediterranean fever	N.A.	Investigative	[3]
------------------------------------------------------------------------------------

Therapeutic Class

Gout Suppressants

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

399.4

Logarithm of the Partition Coefficient (xlogp)

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

BDDCS Class: Biopharmaceutics Drug Disposition Classification System (BDDCS) Class 3: high solubility and low permeability [5]
Clearance: The drug present in the plasma can be removed from the body at the rate of 2.1 mL/min/kg [6]
Half-life: The concentration or amount of drug in body reduced by one-half in 58 hours [6]
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 0.2861 micromolar/kg/day [7]
Unbound Fraction: The unbound fraction of drug in plasma is 0.61% [6]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 6.1 L/kg [6]
Water Solubility: The ability of drug to dissolve in water is measured as 45 mg/mL [5]

Chemical Identifiers

Formula: C22H25NO6
IUPAC Name: N-[(7S)-1,2,3,10-tetramethoxy-9-oxo-6,7-dihydro-5H-benzo[a]heptalen-7-yl]acetamide
Canonical SMILES: CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC
InChI: InChI=1S/C22H25NO6/c1-12(24)23-16-8-6-13-10-19(27-3)21(28-4)22(29-5)20(13)14-7-9-18(26-2)17(25)11-15(14)16/h7,9-11,16H,6,8H2,1-5H3,(H,23,24)/t16-/m0/s1
InChIKey: IAKHMKGGTNLKSZ-INIZCTEOSA-N

Cross-matching ID

PubChem CID: 6167
ChEBI ID: CHEBI:27882
CAS Number: 64-86-8
DrugBank ID: DB01394
TTD ID: D09DHY
VARIDT ID: DR00135
INTEDE ID: DR0372
ACDINA ID: D00149

Combinatorial Drugs (CBD)

Click to Jump to the Detailed CBD Information of This Drug

Repurposed Drugs (RPD)

Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Tubulin (TUB)	TTML2WA	NOUNIPROTAC	Binder	[8]

------------------------------------------------------------------------------------

Drug Transporter (DTP)

DTP Name	DTP ID	UniProt ID	MOA	REF
Multidrug resistance-associated protein 1 (ABCC1)	DTSYQGK	MRP1_HUMAN	Substrate	[9]
P-glycoprotein 1 (ABCB1)	DTUGYRD	MDR1_HUMAN	Substrate	[10]

------------------------------------------------------------------------------------

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 3A4 (CYP3A4)_{Main DME}	DE4LYSA	CP3A4_HUMAN	Substrate	[11]

------------------------------------------------------------------------------------

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
5'-AMP-activated protein kinase subunit beta-1 (PRKAB1)	OT1OG4QZ	AAKB1_HUMAN	Gene/Protein Processing	[12]
Acetylcholinesterase (ACHE)	OT2H8HG6	ACES_HUMAN	Gene/Protein Processing	[13]
Albumin (ALB)	OTVMM513	ALBU_HUMAN	Gene/Protein Processing	[14]
Angiotensin-converting enzyme 2 (ACE2)	OTTRZGU7	ACE2_HUMAN	Gene/Protein Processing	[15]
Apoptosis regulator BAX (BAX)	OTAW0V4V	BAX_HUMAN	Gene/Protein Processing	[16]
Apoptosis regulator Bcl-2 (BCL2)	OT9DVHC0	BCL2_HUMAN	Gene/Protein Processing	[16]
Aryl hydrocarbon receptor (AHR)	OTFE4EYE	AHR_HUMAN	Gene/Protein Processing	[17]
Ataxin-1 (ATXN1)	OTQF0HNR	ATX1_HUMAN	Gene/Protein Processing	[12]
ATP-binding cassette sub-family A member 13 (ABCA13)	OTTHTUQN	ABCAD_HUMAN	Drug Response	[18]
ATP-dependent translocase ABCB1 (ABCB1)	OTEJROBO	MDR1_HUMAN	Gene/Protein Processing	[19]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Acute gout flare

ICD Disease Classification

FA25.0

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Tubulin (TUB)	DTT	NO-GeName	7.94E-02	0.35	0.43
P-glycoprotein 1 (ABCB1)	DTP	P-GP	1.53E-04	-6.93E-01	-2.04E+00
Multidrug resistance-associated protein 1 (ABCC1)	DTP	MRP1	1.01E-02	8.86E-01	1.34E+00
Cytochrome P450 3A4 (CYP3A4)	DME	CYP3A4	2.96E-01	-3.35E-01	-1.10E+00

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Colchicine (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ivosidenib	DM8S6T7	Moderate	Increased metabolism of Colchicine caused by Ivosidenib mediated induction of CYP450 enzyme.	Acute myeloid leukaemia [2A60]	[20]
Arn-509	DMT81LZ	Moderate	Accelerated clearance of Colchicine due to the transporter induction by Arn-509.	Acute myeloid leukaemia [2A60]	[21]
Dronedarone	DMA8FS5	Major	Decreased metabolism of Colchicine caused by Dronedarone mediated inhibition of CYP450 enzyme.	Angina pectoris [BA40]	[22]
Dalfopristin	DM4LTKV	Major	Decreased metabolism of Colchicine caused by Dalfopristin mediated inhibition of CYP450 enzyme.	Bacterial infection [1A00-1C4Z]	[23]
Erdafitinib	DMI782S	Moderate	Decreased clearance of Colchicine due to the transporter inhibition by Erdafitinib.	Bladder cancer [2C94]	[24]
Tucatinib	DMBESUA	Major	Decreased metabolism of Colchicine caused by Tucatinib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[22]
Palbociclib	DMD7L94	Moderate	Decreased metabolism of Colchicine caused by Palbociclib mediated inhibition of CYP450 enzyme.	Breast cancer [2C60-2C6Y]	[25]
MK-8228	DMOB58Q	Major	Decreased metabolism of Colchicine caused by MK-8228 mediated inhibition of CYP450 enzyme.	Cytomegaloviral disease [1D82]	[22]
Stiripentol	DMMSDOY	Major	Decreased metabolism of Colchicine caused by Stiripentol mediated inhibition of CYP450 enzyme.	Epilepsy/seizure [8A61-8A6Z]	[22]
Boceprevir	DMBSHMF	Major	Decreased metabolism of Colchicine caused by Boceprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[22]
Telaprevir	DMMRV29	Major	Decreased metabolism of Colchicine caused by Telaprevir mediated inhibition of CYP450 enzyme.	Hepatitis virus infection [1E50-1E51]	[22]
Brentuximab vedotin	DMWLC57	Moderate	Increased risk of peripheral neuropathy by the combination of Colchicine and Brentuximab vedotin.	Hodgkin lymphoma [2B30]	[26]
Cobicistat	DM6L4H2	Major	Decreased metabolism of Colchicine caused by Cobicistat mediated inhibition of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[22]
Etravirine	DMGV8QU	Moderate	Increased metabolism of Colchicine caused by Etravirine mediated induction of CYP450 enzyme.	Human immunodeficiency virus disease [1C60-1C62]	[27]
Tolvaptan	DMIWFRL	Moderate	Decreased clearance of Colchicine due to the transporter inhibition by Tolvaptan.	Hypo-osmolality/hyponatraemia [5C72]	[28]
Berotralstat	DMWA2DZ	Major	Decreased metabolism of Colchicine caused by Berotralstat mediated inhibition of CYP450 enzyme.	Innate/adaptive immunodeficiency [4A00]	[22]
Ceritinib	DMB920Z	Major	Decreased metabolism of Colchicine caused by Ceritinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[22]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Colchicine caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[29]
Osimertinib	DMRJLAT	Moderate	Decreased metabolism of Colchicine caused by Osimertinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[21]
Selpercatinib	DMZR15V	Moderate	Decreased metabolism of Colchicine caused by Selpercatinib mediated inhibition of CYP450 enzyme.	Lung cancer [2C25]	[21]
Idelalisib	DM602WT	Major	Decreased metabolism of Colchicine caused by Idelalisib mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[22]
IPI-145	DMWA24P	Major	Decreased metabolism of Colchicine caused by IPI-145 mediated inhibition of CYP450 enzyme.	Mature B-cell leukaemia [2A82]	[22]
Blinatumomab	DMGECIJ	Moderate	Decreased metabolism of Colchicine caused by Blinatumomab mediated inhibition of CYP450 enzyme.	Mature B-cell lymphoma [2A85]	[30]
Ibrutinib	DMHZCPO	Moderate	Decreased clearance of Colchicine due to the transporter inhibition by Ibrutinib.	Mature B-cell lymphoma [2A85]	[21]
Exjade	DMHPRWG	Moderate	Decreased metabolism of Colchicine caused by Exjade mediated inhibition of CYP450 enzyme.	Mineral absorption/transport disorder [5C64]	[31]
Carfilzomib	DM48K0X	Moderate	Decreased clearance of Colchicine due to the transporter inhibition by Carfilzomib.	Multiple myeloma [2A83]	[21]
Omacetaxine mepesuccinate	DMPU2WX	Moderate	Additive myelosuppressive effects by the combination of Colchicine and Omacetaxine mepesuccinate.	Myeloproliferative neoplasm [2A20]	[32]
Netupitant	DMEKAYI	Major	Decreased metabolism of Colchicine caused by Netupitant mediated inhibition of CYP450 enzyme.	Nausea/vomiting [MD90]	[23]
Entrectinib	DMMPTLH	Moderate	Decreased metabolism of Colchicine caused by Entrectinib mediated inhibition of CYP450 enzyme.	Non-small cell lung cancer [2C25]	[33]
Olaparib	DM8QB1D	Moderate	Decreased clearance of Colchicine due to the transporter inhibition by Olaparib.	Ovarian cancer [2C73]	[28]
Abametapir	DM2RX0I	Moderate	Decreased metabolism of Colchicine caused by Abametapir mediated inhibition of CYP450 enzyme.	Pediculosis [1G00]	[34]
Lefamulin	DME6G97	Moderate	Decreased metabolism of Colchicine caused by Lefamulin mediated inhibition of CYP450 enzyme.	Pneumonia [CA40]	[35]
Lonafarnib	DMGM2Z6	Major	Decreased metabolism of Colchicine caused by Lonafarnib mediated inhibition of CYP450 enzyme.	Premature ageing appearance [LD2B]	[22]
Enzalutamide	DMGL19D	Moderate	Increased metabolism of Colchicine caused by Enzalutamide mediated induction of CYP450 enzyme.	Prostate cancer [2C82]	[36]
Temsirolimus	DMS104F	Moderate	Increased plasma concentrations of Colchicine and Temsirolimus due to competitive inhibition of the same metabolic pathway.	Renal cell carcinoma [2C90]	[37]
Voxelotor	DMCS6M5	Major	Decreased metabolism of Colchicine caused by Voxelotor mediated inhibition of CYP450 enzyme.	Sickle-cell disorder [3A51]	[22]
Larotrectinib	DM26CQR	Moderate	Decreased metabolism of Colchicine caused by Larotrectinib mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[28]
Armodafinil	DMGB035	Minor	Increased metabolism of Colchicine caused by Armodafinil mediated induction of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[38]
LEE011	DMMX75K	Major	Decreased metabolism of Colchicine caused by LEE011 mediated inhibition of CYP450 enzyme.	Solid tumour/cancer [2A00-2F9Z]	[22]
Fostamatinib	DM6AUHV	Moderate	Decreased clearance of Colchicine due to the transporter inhibition by Fostamatinib.	Thrombocytopenia [3B64]	[39]
Brilinta	DMBR01X	Moderate	Decreased metabolism of Colchicine caused by Brilinta mediated inhibition of CYP450 enzyme.	Thrombosis [DB61-GB90]	[21]
Valganciclovir	DMS2IUH	Moderate	Additive myelosuppressive effects by the combination of Colchicine and Valganciclovir.	Virus infection [1A24-1D9Z]	[28]
-----------


⏷ Show the Full List of 42 DDI Information of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG

DIG Name	DIG ID	PubChem CID	Functional Classification
Allura red AC dye	E00338	33258	Colorant
FD&C blue no. 1	E00263	19700	Colorant
FD&C blue no. 2	E00446	2723854	Colorant
Quinoline yellow WS	E00309	24671	Colorant
Beta-D-lactose	E00099	6134	Diluent; Dry powder inhaler carrier; Lyophilization aid
FD&C red no. 3	E00629	Not Available	Colorant
Lactose monohydrate	E00393	104938	Binding agent; Diluent; Dry powder inhaler carrier; Lyophilization aid
Magnesium stearate	E00208	11177	lubricant
Silicon dioxide	E00670	Not Available	Anticaking agent; Opacifying agent; Viscosity-controlling agent
Titanium dioxide	E00322	26042	Coating agent; Colorant; Opacifying agent
Triacetin	E00080	5541	Humectant; Plasticizing agent; Solvent
Water	E00035	962	Solvent
--------------------


⏷ Show the Full List of 12 Pharmaceutical Excipients of This Drug

Pharmaceutical Formulation

Formulation Name	Drug Dosage	Dosage Form	Route
Colchicine 0.6 mg capsule	0.6 mg	Oral Capsule	Oral
Colchicine 0.6 mg tablet	0.6 mg	Oral Tablet	Oral

Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1	FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (NDA) 022351
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7526).
3	Colchicine FDA Label
4	ClinicalTrials.gov (NCT04322565) Colchicine Counteracting Inflammation in COVID-19 Pneumonia. U.S. National Institutes of Health.
5	BDDCS predictions, self-correcting aspects of BDDCS assignments, BDDCS assignment corrections, and classification for more than 175 additional drugs
6	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
7	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
8	Vitamin K3 disrupts the microtubule networks by binding to tubulin: a novel mechanism of its antiproliferative activity. Biochemistry. 2009 Jul 28;48(29):6963-74.
9	Pharmacological characterization of the murine and human orthologs of multidrug-resistance protein in transfected human embryonic kidney cells. Mol Pharmacol. 1997 Sep;52(3):344-53.
10	Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters. Biochem Pharmacol. 2009 Jul 15;78(2):153-61.
11	Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol Pharmacol. 2003 Jul;64(1):160-9.
12	Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity. Toxicology. 2014 Jan 6;315:8-16. doi: 10.1016/j.tox.2013.10.009. Epub 2013 Nov 6.
13	Dihydroactinidiolide regulates Nrf2/HO-1 expression and inhibits caspase-3/Bax pathway to protect SH-SY5Y human neuroblastoma cells from oxidative stress induced neuronal apoptosis. Neurotoxicology. 2021 May;84:53-63. doi: 10.1016/j.neuro.2021.02.006. Epub 2021 Feb 20.
14	[Colchicine in chronic liver disease of alcoholic etiology. Double-blind, randomized study of its effects on blood levels of plasma proteins and clinical course in patients]. Rev Assoc Med Bras (1992). 1995 May-Jun;41(3):207-12.
15	Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue. Arch Toxicol. 2020 Dec;94(12):4037-4041. doi: 10.1007/s00204-020-02869-1. Epub 2020 Aug 17.
16	Colchicine-induced apoptosis in human normal liver L-02 cells by mitochondrial mediated pathways. Toxicol In Vitro. 2012 Aug;26(5):649-55. doi: 10.1016/j.tiv.2012.01.024. Epub 2012 Feb 8.
17	Involvement of cytoskeleton in AhR-dependent CYP1A1 expression. Curr Drug Metab. 2006 Apr;7(3):301-13. doi: 10.2174/138920006776359310.
18	Population-based in vitro hazard and concentration-response assessment of chemicals: the 1000 genomes high-throughput screening study. Environ Health Perspect. 2015 May;123(5):458-66. doi: 10.1289/ehp.1408775. Epub 2015 Jan 13.
19	Analysis of ATP-binding cassette transporter expression in drug-selected cell lines by a microarray dedicated to multidrug resistance. Mol Pharmacol. 2004 Dec;66(6):1397-405. doi: 10.1124/mol.104.005009. Epub 2004 Sep 1.
20	Product Information. Tibsovo (ivosidenib). Agios Pharmaceuticals, Cambridge, MA.
21	Cerner Multum, Inc. "UK Summary of Product Characteristics.".
22	Akdag I, Ersoy A, Kahvecioglu S, Gullulu M, Dilek K "Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure." J Nephrol 19 (2006): 515-7. [PMID: 17048210]
23	Dogukan A, Oymak FS, Taskapan H, Guven M, Tokgoz B, Utas C "Acute fatal colchicine intoxication in a patient on continuous ambulatory peritoneal dialysis (CAPD). Possible role of clarithromycin administration." Clin Nephrol 55 (2001): 181-2. [PMID: 11269688]
24	Product Information. Balversa (erdafitinib). Janssen Products, LP, Horsham, PA.
25	Product Information. Ibrance (palbociclib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
26	Carrion C, Espinosa E, Herrero A, Garcia B "Possible vincristine-isoniazid interaction." Ann Pharmacother 29 (1995): 201. [PMID: 7756727]
27	Product Information. Intelence (etravirine). Ortho Biotech Inc, Bridgewater, NJ.
28	Cerner Multum, Inc. "Australian Product Information.".
29	Product Information. Lorbrena (lorlatinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
30	Product Information. Blincyto (blinatumomab). Amgen USA, Thousand Oaks, CA.
31	Product Information. Exjade (deferasirox). Novartis Pharmaceuticals, East Hanover, NJ.
32	Product Information. Synribo (omacetaxine). Teva Pharmaceuticals USA, North Wales, PA.
33	Product Information. Rozlytrek (entrectinib). Genentech, South San Francisco, CA.
34	Product Information. Xeglyze (abametapir topical). Dr. Reddy's Laboratories Inc, Upper Saddle River, NJ.
35	Product Information. Xenleta (lefamulin). Nabriva Therapeutics US, Inc., King of Prussia, PA.
36	Benoist G, van Oort I, et al "Drug-drug interaction potential in men treated with enzalutamide: Mind the gap." Br J Clin Pharmacol 0 (2017): epub. [PMID: 28881501]
37	Product Information. Prograf (tacrolimus). Fujisawa, Deerfield, IL.
38	Doherty MM, Charman WN "The mucosa of the small intestine: how clinically relevant as an organ of drug metabolism?" Clin Pharmacokinet 41 (2002): 235-53. [PMID: 11978143]
39	Product Information. Tavalisse (fostamatinib). Rigel Pharmaceuticals, South San Francisco, CA.